Novartis AG (NOVN.S)
20 Feb 2018
Note: Reuters has not verified this story and cannot vouch for its accuracy. (New York Newsroom)
Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.
Feb 16 Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.
* NOVARTIS FORMS ALLIANCE TO DEVELOP MEDICINES FOR TREATING INFECTIOUS DIARRHEAL DISEASE
ZURICH Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market.
* U.S. pricing pressure weighing on Sandoz (Adds Teva comment, share price reaction)
ZURICH, Feb 13 Novartis's Sandoz division said on Tuesday it has won approval in the United States for a larger dosage of its Glatopa treatment for multiple sclerosis patients.
ATHENS/ZURICH Greece's prime minister urged parliament on Monday to probe politicians in an alleged drug bribery case, while Swiss drugmaker Novartis promised to take action if an investigation found unethical conduct.
ZURICH, Feb 12 Swiss drugmaker Novartis has promised to take "fast and decisive action" should an investigation into alleged bribery in Greece find that its managers engaged in unethical or illegal conduct.
LONDON, Feb 8 GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division.